Atagabalin
Подписчиков: 0, рейтинг: 0
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider |
|
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C10H19NO2 |
| Molar mass | 185.267 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
|
| |
Atagabalin (PD-0200,390) is a drug developed by Pfizer and related to gabapentin, which similarly binds to the α2δ calcium channels (1 and 2). It was under development as a treatment for insomnia, but was discontinued following unsatisfactory trial results.
See also
| Calcium |
|
||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Potassium |
|
||||||||||||||||||||||||
| Sodium |
|
||||||||||||||||||||||||
| Chloride |
|
||||||||||||||||||||||||
| Others |
|
||||||||||||||||||||||||